These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial. Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187 [TBL] [Abstract][Full Text] [Related]
13. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751 [TBL] [Abstract][Full Text] [Related]
14. T10B9 action: the effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response. Brown S; Lucas B; Waid T; McKeown W; Tsuchida M; Thompson J Transplant Proc; 1997; 29(1-2):315-6. PubMed ID: 9123017 [No Abstract] [Full Text] [Related]
15. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095 [TBL] [Abstract][Full Text] [Related]